TARS - NASDAQ
Tarsus Pharmaceuticals, Inc.
$58.76
-0.29%Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
At a Glance
Live SnapshotTarsus Pharmaceuticals, Inc. Management Team
Mr. Aziz Mottiwala M.B.A.
Chief Commercial Officer
Compensation
$836,505
Mr. Jeffrey S. Farrow CPA
Chief Financial Officer & Chief Strategy Officer
Compensation
$930,569
Dr. Elizabeth Yeu M.D.
Chief Medical Officer
Compensation
$156,691
Dr. Seshadri Neervannan Ph.D.
Chief Operating Officer
Compensation
$892,332
Dr. Bobak R. Azamian M.D.
Co-Founder, President, Chief Executive Officer & Chairman
Compensation
$1,258,347
Dr. Bryan Wahl J.D., M.D.
General Counsel & Corporate Secretary
Compensation
$619,087
Mr. David Nakasone
Head of Investor Relations
Ms. Adrienne Kemp
Senior Director of Corporate Communications
Mr. Matthew Rossen M.B.A.
Vice President of Marketing
Mr. Scott Youmans
Vice President of Sales
Tarsus Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have sold $12.77M worth of TARS shares, with no buying activity reported.
3 Months
0
0.00
97.9K
6.68M
-6.7M
-$6.68M
3-6 Months
0
0.00
32.0K
2.55M
-2.5M
-$2.55M
6-9 Months
0
0.00
33.1K
1.88M
-1.9M
-$1.88M
9-12 Months
0
0.00
38.1K
1.66M
-1.7M
-$1.66M
Top Buyers
No buying activity
Top Sellers
Azamian Bobak R.
Director, Officer: President/Ceo And Board Chair
$3.45M
Link William J Phd
Director
$2.20M
Whitfield Dianne C.
Officer: Chief Human Resources Officer
$1.89M
Mottiwala Aziz
Officer: Chief Commercial Officer
$1.66M
Neervannan Seshadri
Officer: Chief Operating Officer
$1.61M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $12.77M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
TARS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 25, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A 2022 N/A | April 26, 2023 | December 31, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | May 02, 2022 | June 16, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 15, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.